


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I)



wherein:

T and W independently represent CR<sup>1</sup> or N; and when more than one R<sup>1</sup> group is present, each may be selected independently;

X and R<sup>1</sup> independently represent H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to Claim 1 wherein Y represents CN or halogen.
3. (Currently Amended) A compound according to Claim 1 [[or 2]] wherein X and R<sup>1</sup> independently represent H, halogen or CF<sub>3</sub>.

4. (Original) A compound of formula (I), according to Claim 1, which is:

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile;  
(2*S*,4*R*)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol;  
2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)- 3-pyridinecarbonitrile;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile;  
or a pharmaceutically acceptable salt thereof.

5. (Cancelled)

6. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) according to Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

7-12. (Cancelled)

13. (Previously Presented) A method for the treatment or prophylaxis of pain comprising administering a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

14. (Previously Presented) A method for the treatment or prophylaxis of an inflammatory disease comprising administering a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, and a COX-2 inhibitor.


15. (Previously Presented) A method of treating, or reducing the risk of, a human disease or condition in which inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

16. (Previously Presented) A method according to Claim 15 in which it is predominantly inducible nitric oxide synthase that is inhibited.


17. (Currently Amended) A method of treating, or reducing the risk of, an inflammatory disease selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, and osteoarthritis in a person suffering from, ~~or at risk of~~, said disease, wherein the method comprises administering a therapeutically effective amount of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

18. (Previously Presented) A process for the preparation of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the process comprises:

(a) reaction of a compound of formula (II)




wherein T, X, Y and W are as defined in Claim 1 and L<sup>1</sup> represents a leaving group, with a compound of formula (III)




or

(b) reaction of a compound of formula (IV)



wherein T, W, X and Y are as defined in Claim 1,  
with a compound of formula (V)



wherein  $L^2$  is a leaving group.

19. (Previously Presented) A process as defined in Claim 18, further comprising:  
converting the resultant compound of formula (I) into a pharmaceutically acceptable salt thereof; converting the resultant compound of formula (I) into another compound of formula (I); or converting the resultant compound of formula (I) into an optical isomer thereof.

20. (Previously Presented) A compound according to Claim 2, wherein X and  $R^1$  independently represent H, halogen or  $CF_3$ .

21. (Previously Presented) The method as claimed in Claim 17, wherein the inflammatory disease is inflammatory bowel disease.

22. (Previously Presented) The method as claimed in Claim 17, wherein the inflammatory disease is rheumatoid arthritis.

23. (Previously Presented) The method as claimed in Claim 17, wherein the inflammatory disease is osteoarthritis.